Durvalumab
- IV infusionDurvalumabImfinzi
- Mechanism of Action
- A monoclonal antibody directed against PD-L1, an inhibitory molecule expressed on certain tumour cells.
- PD-L1 and PD-L2 are ligands that bind to PD-1 receptors on activated lymphocytes and inhibit T cell receptor signalling, downregulating immune responses and promoting tolerance.
- Binding of anti-PD-L1 monoclonal antibodies leaves the ligand unable to bind to PD-1, and therefore stimulates an ongoing immune response.
- PD-L2 is not inhibited, allowing PD-1 / PD-L2 mediated inhibitory signals to continue.
Clinical Use
- Indications
- Locally advanced non-small cell lung cancer (NSCLC) without progression post chemoradiotherapy
- Locally advanced or metastatic urothelial carcinoma with progression post platnium-based chemotherapy
- Adverse Effects
- Endocrinopathies - thyroiditis, adrenalitis, hypophysitis, diabetes mellitus
- Pulmonary toxicity - pneumonitis
- Hepatotoxicity - LFT derangement, hepatitis
- GI toxicity - colitis
- Rheumatological - flares of previous disease
- Skin - rash, pruritis
- Fatigue
- Anorexia
- Headache
- Dizziness
- Nausea / vomiting / diarrhoea
- Thrombocytopaenia